Acute myeloid leukemia (AML) is the most common acute leukemia affecting adults, and its incidence increases with age. The minority of patients are cured by current therapy and the majority relapse within 5 years despite continuous treatment. Cancer stem cells (CSCs), which have the capacity for indefinite self-renewal, may be essential for tumor initiation and relapse. New targets are needed to efficiently inhibit CSC activity. Most recently, we identified the immune inhibitory receptors, human leukocyte immunoglobulin (Ig)-like receptor B2 (LILRB2) and its mouse ortholog paired Ig-like receptor (PirB), as receptors for Angiopoietin-like proteins (Angptls). Previous studies showed that several Angptls promote cancer development, whereas immune inhibitory receptors suppress the immune activation to support cancer growth. Our preliminary research showed that LILRB2 level is significantly elevated in the M5 subtype of human AML. Angptls bind to LILRB2 and to PirB and induce activation of tyrosine phosphotase SHP-2 and calcium/calmodulin-dependent protein kinase 4 (CAMK4). A deficiency of PirB in two mouse AML models resulted in increased differentiation and decreased self-renewal of leukemia stem cells. Concordantly, the knockdown of LILRB2 in two human leukemia cell lines largely blocked leukemia development in xenografted mice. These results indicate that LILRB2 and PirB support leukemia development. Therefore, our study revealed unexpected functional significance of classical immune inhibitory receptors in the maintenance of stemness of cancer stem cells. We hypothesize that Angptls bind LILRB2 and PirB to inhibit differentiation and promote self-renewal through activating SHP-2 and CAMK4. We propose three aims to test this hypothesis.
In Aim 1, we will determine the role of LILRB2 and its ligand binding in regulation of primary human AML-SC activity.
In Aim 2, we will dissect the Angptl receptor initiated signaling pathway in AML-SCs, using gain-of-function and loss-of- function approaches to illuminate the functional significance of the SHP-2 signaling and CAMK4 signaling in regulation of self-renewal and differentiation of AML-SCs.
In Aim 3, we will investigate how the downstream targets of the Angptl receptor-mediated signaling regulate AML-SC activity. To our knowledge, this is the first study of the molecular mechanism of these """"""""inhibitory receptors"""""""" in the maintenance of stemness of cancer stem cells and progenitors. The proposed study will determine the functional significance of the Angptl receptor in human AML and identify the molecular determinants of the Angptl receptor-mediated signaling in control of AML-SC activity. It will likely open a new research front to study the role of inhibitory receptors in stem cells and cancer. Moreover, the understanding of the ligand-receptor binding, the signaling events, and the downstream effectors in this newly identified pathway will directly guide the development of new therapeutic strategies for human AML.

Public Health Relevance

Our study suggest that Angiopoietin-like proteins and their receptors are promising anti-cancer targets. The successful completion of our study will, for the first time, reveal how Angiopoietin-like proteins and their receptors support acute myeloid leukemia development and maintain stemness of cancer stem cells. It will lead to the development of novel strategies to treat human acute myeloid leukemia and perhaps other cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Mufson, R Allan
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Sw Medical Center Dallas
Schools of Medicine
United States
Zip Code
Zhang, Yaping; Xia, Fangzhen; Liu, Xiaoye et al. (2018) JAM3 maintains leukemia-initiating cell self-renewal through LRP5/AKT/?-catenin/CCND1 signaling. J Clin Invest 128:1737-1751
Zhou, Zhan; Zheng, Yuhui; Zhang, Cheng Cheng et al. (2018) In vitro and in vivo studies of a chlorin-based carbon nanocarrier with photodynamic therapy features. Photochem Photobiol Sci 17:1329-1336
Jiang, Linjia; Han, Xue; Wang, Jin et al. (2018) SHP-1 regulates hematopoietic stem cell quiescence by coordinating TGF-? signaling. J Exp Med 215:1337-1347
Deng, Mi; Gui, Xun; Kim, Jaehyup et al. (2018) LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature 562:605-609
Kang, Xunlei; Cui, Changhao; Wang, Chen et al. (2018) CAMKs support development of acute myeloid leukemia. J Hematol Oncol 11:30
Lu, Zhigang; Xie, Jingjing; Wu, Guojin et al. (2017) Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation. Nat Med 23:79-90
Zhang, Feifei; Liu, Xiaoye; Chen, Chiqi et al. (2017) CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27kip1 signaling. Haematologica 102:707-718
Chen, Chen; Yin, Yancun; Li, Chunling et al. (2016) ACER3 supports development of acute myeloid leukemia. Biochem Biophys Res Commun 478:33-38
Kang, Xunlei; Kim, Jaehyup; Deng, Mi et al. (2016) Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors. Cell Cycle 15:25-40
Constanzo, Jerfiz D; Deng, Mi; Rindhe, Smita et al. (2016) Pias1 is essential for erythroid and vascular development in the mouse embryo. Dev Biol 415:98-110

Showing the most recent 10 out of 28 publications